Amiodarone, a benzofuranic iodine-rich antiarrhythmic drug, causes thyroid dysfunction in 15-20% of cases. Amiodarone can cause both hypothyroidism (AIH, amiodarone-induced hypothyroidism) and thyrotoxicosis (AIT, amiodarone-induced thyrotoxicosis). AIH is treated by L-thyroxin replacement and does not need amiodarone discontinuation. There are two main forms of AIT: type 1, a form of true iodineinduced hyperthyroidism; and type 2, a drug-induced destructive thyroiditis. However, mixed/indefinite forms exist, contributed to by both pathogenic mechanisms. Type 1 AIT usually occurs in diseased thyroid glands, whereas type 2 AIT develops in substantially normal thyroid glands. Thioamides represent the first-line treatment for type 1 AIT, but iodine-replete glands are poorly responsive; sodium/ /potassium perchlorate, by inhibiting thyroidal iodine uptake, may increase the response to thioamides. Type 2 AIT is best treated by oral glucocorticoids. Response depends on thyroid volume and severity of thyrotoxicosis. Mixed/indefinite forms may require a combination of thioamides, potassium perchlorate, and steroids. Radioiodine treatment is usually not feasible because amiodarone-related iodine load decreases thyroidal radioiodine uptake. Thyroidectomy represents an important and helpful option in cases resistant to medical therapy. Surgery performed by a skilled surgeon may represent an emergent treatment in patients who have severe cardiac dysfunction. 
Introduction
Amiodarone (AMIO) is the most commonly used antiarrhythmic drug worldwide [1] . AMIO, a class III antiarrhythmic agent, was originally developed four decades ago as a potent coronary vasodilator and antianginal agent [1] . Its antiarrhythmic properties were recognised in 1969, and the US Food and Drug Administration (FDA) approved the drug for recurrent life-threatening ventricular arrhythmias in 1985 [2, 3] . Currently, AMIO is used for a variety of supraventricular and ventricular arrhythmias even though the FDA still approves it only for use in refractory ventricular arrhythmias.
Inhibition of conversion of T4 to T3
It is widely accepted that the effects of AMIO on thyroid hormone plasma concentrations are at least in part due to interference with the iodothyronine deiodinases [12, 13] . AMIO inhibits monodeiodination (5-deiodinase activity; D1 and D2) of T4. This leads to a decrease in the generation of T3 from T4, a decrease in the clearance of reverse T3 (rT3), and consequently increased rT3 accumulation [14] .
Similarity to T3
The chemical structures of AMIO and DEA are very similar to T3, and some of its effects have been attributed to inhibition of thyroid hormone transport across the plasma membrane [15] , and/or direct binding to the thyroid hormone receptors [16, 17] , and possibly even thyroid receptor (TR)-dependent gene transcription [18] .
Furthermore, DEA is a non-competitive inhibitor of the binding of thyroid hormone (T3) to thyroid receptor (TR) b [19] . These actions contribute to some hypothyroid-like effects observed in euthyroid subjects under AMIO therapy, including a transient increase in serum TSH concentration [20] . Treatment with AMIO reduces expression of thyroid hormone sensitive genes and causes down-regulation of myocardial genes, including sarco/endoplasmic reticulum calcium ATPase-2 (SERCA2A) and myosin heavy chain (aMHC) and increased bMHC, all features observed in hypothyroidism [21, 22] . In addition, down-regulation of the hepatic LDL receptor, leading to an increase in serum cholesterol concentrations, has been attributed to a direct effect of AMIO on the LDL receptor gene expression [23] .
Destruction of thyroid cells
AMIO and DEA also have direct toxicity on thyroid cells, although excess iodine per se might be responsible for cytotoxicity [24] .
Serum thyroid hormone levels change during AMIO treatment
TSH is the first hormone level to change, rising within 48 hours and increasing up to an average of 2.7 times the normal levels by the 10 th day [25] . At the beginning of therapy the Wolff-Chaikoff effect occurs, decreasing T4, T3 concentration, but later on (about two weeks) the thyroid gland shows an escape phenomenon. There is an early and measureable rise in serum T4, rT3 and free T4, which peak after 10 weeks of treatment [11] . Conversely, there is a reciprocal and early fall in serum T3 level over a similar time course. By three months a steady state is generally reached with serum total and free T4 and rT3 levels remaining at the upper end of the normal range or marginally elevated. T3 levels tend to remain at the lower end of the normal range after three months, with TSH at the upper end of normal range. During chronic AMIO therapy, a decrease in serum TSH concentration may occur [2] (Table I) .
Adverse events of chronic AMIO therapy
Prolonged administration of AMIO can be associated with several adverse events (Table II) , including rela- Table I . Changes in thyroid function tests in euthyroid patients under chronic AMIO therapy
Serum hormone level Early effects (< 3 months) Late effects (> 3 months)
fT4 and TT4 ≠50% ≠20-40% of baseline values (may be slightly above the reference value) T3
Ø15-20%
Remains in the low/low-normal ranges TSH ≠20-50%, transient Normal
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tively frequent thyroid dysfunction [26] . Although most patients are euthyroid during AMIO treatment, about 15-20% develop thyroid dysfunction, ranging from asymptomatic laboratory test abnormalities to overt disease, either AMIO-induced hypothyroidism (AIH) or AMIO-induced thyrotoxicosis (AIT) [27] . Thyroid dysfunction may occur at any time during AMIO therapy [28] . Thus, periodical monitoring of thyroid function is warranted before therapy, during therapy, and even 6-12 months after AMIO discontinuation.
In spite of AMIO-induced thyroid disorder, it is important to remember other side effects of this medication (Table 2) because particularly pulmonary and liver toxicity may aggravate the course of AIT [29] .
Thyroid evaluation during AMIO therapy
Baseline evaluation should include: -TSH and fT4 (and fT3, if necessary); -thyroid-directed autoantibodies [anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-TG)]; -thyroid ultrasonography (US). Although most endocrine societies do not recommend routine US examination, it is helpful in countries with large incidence of thyroid nodular disease, and may suggest or confirm autoimmune thyroid disease.
Patients with decreased (suppressed) serum TSH should undergo further evaluation, including measurement of serum TSH-receptor antibody (TRAb) levels and thyroid scintigraphy [30] . In patients with subclinical hyperthyroidism due to thyroid autonomy (toxic adenoma or latent Graves' disease), one should consider thyroid ablation (radioiodine or surgery), if possible and allowed by cardiac conditions, before starting AMIO treatment. During therapy, assessment of thyroid function should be assessed at least every six months. Monitoring of thyroid function tests before and at 1 and 3 months following the initiation of AMIO therapy, and at 3-6-month intervals thereafter is suggested. Measurement of thyroid-directed autoantibodies is not recommended during follow up because AMIO therapy is probably not associated with development of thyroid autoimmune phenomena.
Amiodarone-induced thyrotoxicosis
AIT has a higher male-to-female ratio of 3:1 [31] . AIT usually develops after months of AMIO treatment, but it can develop in the first few weeks of therapy [32] . The onset time of AIT depends on AIT type, being shorter in type 1 than in type 2 AIT (see below) [33] . Thyroid volume also affects the onset time [33] . Furthermore, because of the prolonged half-life of AMIO, AIT can also develop several months after AMIO withdrawal [34] . There are two main types of AIT. Type 1 AIT usually occurs in patients with underlying thyroid pathology, such as latent Graves' disease or nodular goitre. In these patients the sudden iodide load associated with AMIO administration triggers excess thyroid hormone synthesis and induces true hyperthyroidism (Jod-Basedow phenomenon) [26] .
Type 2 AIT occurs in a substantially normal/slightly enlarged thyroid gland and results from a direct toxic effect of AMIO (or iodine) causing destructive thyroiditis [24] . Histopathological examination of the thyroid gland confirms an inflammatory response as evidenced by infiltration by histiocytes follicular swelling and fibrosis [35] . It may be difficult to differentiate between these two types of AIT. Indeed, both pathogenic mechanisms may concur to thyrotoxicosis in so-called mixed or indefinite forms of AIT (Table III) .
Type 2 is nowadays the predominant form of AIT, accounting for about 90% of cases, with a changed trend in the last 20 years. The reason is not clear, but it is conceivable that patients who are candidates for elective AMIO treatment are screened for pre-existing 
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thyroid abnormalities more frequently than in the past, prior to AMIO therapy institution [35] .
Clinical features of AIT
Many of the clinical features of AIT are similar to those of thyrotoxicosis of any other aetiology and include weight loss, heat intolerance, fatigue, muscle weakness, increased frequency of stools, oligomenorrhoea, nervousness, anxiety, and palpitations. However, some peculiar features of AIT include: -AIT often occurs in the elderly, may be apathetic with atypical features, such as reduced appetite, absence of distal tremors, and depression [36] . In patients over 60 years of age, more than 50% may have a few symptoms of hyperthyroidism, weight loss being quite common; -the recurrence or exacerbation of the underlying cardiac abnormality during AMIO therapy in a patient with previously stable cardiac conditions may represent the first symptom [37, 38] ; -many patients with atrial fibrillation are treated with warfarin to lower the risk of clinical thromboembolism. Warfarin exerts its anticoagulation effect by inhibiting vitamin-K-dependent clotting factors II, VII, IX, and X. Although the pharmacokinetics of warfarin are unchanged in thyrotoxicosis, the rate of degradation of the coagulation factors dependent on vitamin K is increased in this setting, which results in potentiation of warfarin effects. Therefore, an unexplained change in warfarin sensitivity requiring a decrease in dosage should lead the treating physician to suspect hyperthyroidism [39, 40] . AMIO per se can affect warfarin metabolism irrespective of thyrotoxicosis; the presence of concomitant genetic abnormalities affecting warfarin metabolism (CYP2C9*3/*3, VKORC1*3/*3) may further expose the patient to the risk of overtreatment [41] . Thus, in patients with AIT warfarin therapy should be initiated gradually, starting with low doses; -in spite of the high thyroid hormones concentration, the course of AIT may be poorly symptomatic, especially at onset. An asymptomatic course of AIT may be the reason for misdiagnosis. This may be related to physiological AMIO actions, such as: antagonist effect on b-adrenergic receptors, inhibition of deiodination T4 to the metabolically active T3, and blockade of thyroid hormone binding to T3 receptors in the heart; -on the other hand, AIT may also be heavily symptomatic, especially in younger patients whose clinical manifestations are indistinguishable from those of spontaneous hyperthyroidism [25, 31, 42] .
Differentiation of amiodarone-induced thyrotoxicosis
Most centres recommend differentiation of two main forms of AIT because therapeutic options and outcome may differ [42] . Some centres suggest treating all patients with AIT in the same way (starting with either methimazole -MMI or steroids); however, this approach has to be validated in each country (for example, 
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according to iodine intake) and has not been performed in Poland. Suppressed serum TSH and elevated serum fT4 and fT3 are seen in both main types of AIT and cannot differentiate these two forms. An increased (> 4) T4/T3 ratio is a common feature of destructive thyroiditis [43] , but this is not useful in individual AIT patients because serum fT4 is relatively higher than fT3 in all of them, due to the inhibition of D1 [35] . The search for thyroid-directed autoantibodies (particularly TSH receptor autoantibody) is relevant mainly in AIT patients whose underlying and pre-existing thyroid disorder is Graves' disease [2] . Only 8% of type 2 AIT patients have positive thyroid autoantibody tests. In a subset of patients with euthyroid chronic autoimmune thyroiditis, AMIO may trigger a destructive process leading to AIT type 2. Thus, positivity of thyroid autoantibody tests does not always support diagnosis of the type 1 AI [35, 44] . Other parameters, such as interleukin-6, C-reactive protein, and thyroglobulin, are not useful in clinical practice [45] . Radioiodine uptake (RAIU) is usually low in type 1 AIT, but can also be normal or raised because of avid uptake by autonomous thyroid tissue. Conversely, it is very low or suppressed in type 2 AIT because of destruction or damage of thyroid tissue [26] .
The results of RAIU differ in published studies, probably due to selection of different cohorts of patients and other factors (e.g. iodine intake) that might affect the results [44] . Recently, thyroid [99mTc]2-methoxy-isobutylisonitrile (MIBI) scintigraphy has been proposed as a potentially useful diagnostic tool [46] . In this study, MIBI diffuse retention, suggesting hyperfunctioning tissue, was detected in all type 1 AIT patients, while no uptake, suggesting a destructive process was observed in type 2 AIT; four patients with indefinite AIT had either a slight persistent MIBI uptake or showed a fast tracer washout [46] . Although promising, this diagnostic tool for AIT needs to be validated in larger series and is currently not used in clinical practice. Thyroid US is often revealed an increased thyroid volume, a hypoechogenic pattern, and/or nodular lesions in type 1 AIT, but it is usually normal in type 2 AIT, although there may be a small goitre. However, conventional echography does not provide functional information, and the presence of goitre/nodules does not necessarily identify the mechanism responsible for AIT. Colour flow Doppler sonography may reveal normal/high vascularity (indicating hyperfunctioning gland) in most type 1 AIT or low/absent vascularity (damage to thyroid gland) in type 2 AIT [47, 48] . Expertise in thyroid US is mandatory for proper evaluation.
Distinguishing between types of AIT is important because it has a major influence on subsequent management. A combination of several diagnostic procedures improves differentiation of types of AIT, but may fail in individual cases.
Management of amiodarone-induced thyrotoxicosis
AIT bears a threefold increased rate of major adverse cardiovascular events compared to euthyroid patients, hence prompt implementation of treatment is important [38, 49, 50] . The decision regarding the continuation or otherwise of AMIO is difficult, with no definitive answer. Consideration must be given to the benefit of AMIO on life-threatening arrhythmias, the fact it has such a long half-life (and hence no immediate benefit on thyroid status if withdrawn), and the fact that AMIO reduces T4 to T3 conversion, so an initial exacerbation of thyrotoxic symptoms may occur on its cessation [38, 51] .
It is also relevant that DEA binds to intracellular T3 receptors and acts as a T3 antagonist; hence continuing AMIO and treating with antithyroid drugs (ATDs) might be a feasible option in some patients [19] .
Type 1 AIT
Management of type 1 AIT is based on the use of ATDs, particularly MMI, to block hormone synthesis [14, 50, 52] . In AMIO-treated patients the thyroid gland contains huge amounts of iodine and is thereby resistant to ATD action. Accordingly, very high starting doses of MMI, up to 60 mg/day, may be required. Propylthiouracil (PTU) was once favoured because it additionally inhibits peripheral 5'deiodinase activity. However, the US Food and Drug Administration (FDA) have recently released an advisory on PTU for its liver toxicity potential [53] . Patients on high-dose MMI should be advised about the possible adverse events, particularly bone marrow suppression. To increase the sensitivity of the thyroid gland and the response to thioamides, sodium, or potassium perchlorate, which decreases thyroid iodine uptake, is added for 2-6 weeks. It is recommended not to use doses > 1 g/day, which is sufficient in most patients to minimise the adverse events, especially on the kidney and blood marrow. Perchlorate reduces the intrathyroidal iodine stores because it decreases the entry of iodine into the thyroid and competitively inhibits thyroid iodine uptake [7] . Glucocorticoids are very important in severe cases or mixed cases.
Definitive treatment, by either radioiodine or surgery, after type 1 AIT has been controlled is recommended. The timing of this depends on the severity of thyrotoxicosis, the response to antithyroid drugs, RAIU, and the policy of the supervising endocrinologist. Definitive therapy cures the underlying thyroid disease and makes AMIO retreatment, if needed, feasible without any risk of recurrence of worrisome thyrotoxicosis.
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Type 2 AIT
If AMIO is stopped in patients with type 2 AIT, some of them will become and remain euthyroid within 3-5 months of AMIO withdrawal [44, 54] . Some may eventually become hypothyroid [54] . Type 2 AIT may be self-limiting, and continuation of AMIO has been suggested by some authors not to influence the effectiveness of glucocorticoid treatment [55] . The latter are needed in the majority of patients with overt thyrotoxicosis. Initial prednisone dose is about 0.5--0.7 mg/kg body weight per day, and treatment is usually tapered down and discontinued after three months [2] . Response to treatment often is dramatic, and half of the patients are cured within four weeks [56] . However, a delayed response may be encountered, possibly related to the mixed pathogenesis of AIT. Using a mathematical model, euthyroidism may be predicted to be reached on average after 40 days of treatment [56] . Thioamides are not the first-line treatment in type 2 AIT because the underlying pathogenic mechanism is not an enhanced thyroid hormone synthesis. A recent retrospective cohort study of type 2 AIT showed that after about six weeks of therapy more than 85% of patients treated with ATDs were still thyrotoxic, compared to 24% of prednisone-treated patients [57] . Follow-up of these patients is necessary because disease may recur, thus requiring retreatment [14, 50] . Up to 17% of patients may eventually develop hypothyroidism, depending on the extension and severity of the destructive process [44] . In most cases, biochemical and clinical resolution of thyrotoxicosis begins within days of starting steroid therapy and is complete within the first month of treatment [52] . Iopanoic acid is an iodinated oral cholecystographic agent that inhibits type 2 deiodinase activity and is occasionally used, if available, for a brief period in some thyrotoxic conditions for a prompter control of thyrotoxicosis [58] . However, because of an escape phenomenon and recurrence of thyrotoxicosis, long-term treatment with this drug or other iodinated contrastographic agents is not advisable. Prednisolone is more effective than iopanoic acid, but the latter may be useful if type 2 AIT needs to be rapidly controlled, as in the event that emergent thyroidectomy needs to be performed [58] .
Mixed/indefinite type AIT
In mixed/indefinite type AIT or if diagnosis is uncertain, it is reasonable to start therapy with a combined therapy MMI 40-60 mg/day and prednisone 40-50 mg/day, to avoid delay in restoration of euthyroidism. If there is a rapid response, this may suggest prevailing type 2 phenomena, and consideration can be given to quitting MMI. A poor response may indicate prevailing type 1 phenomena. Gradual tapering of the dose of prednisolone and continuation of MMI may then be necessary. Close follow-up is required. Perchlorate, radioactive iodine (if feasible), or surgery should be considered if the response is not desirable [59] . Amiodarone-induced destructive thyroiditis may occur in patients with goitre, making differentiation of type 1 and mixed/indefinite forms very difficult. In these cases, many experts treat these patients with a combination of ATDs and glucocorticoids from the beginning [60] . Some experts are concerned about the fact that glucocorticoids may not be easy to handle in patients with cardiac diseases; accordingly, it has been suggested by some to start medical therapy of indefinite forms with thioamides for at least a month and to associate steroids only if response is poor or absent [61] . In our view, this somehow expectant strategy may be harmful for a patient with severe cardiac disorders, whose thyrotoxicosis should be promptly corrected.
Therapeutic options in patients with severe AIT
Plasmapheresis
The effectiveness of plasmapheresis is, to say the least, controversial [1] . This procedure is rarely used because of its transient effects and its costs. It has been suggested that plasmapheresis is effective when drug treatment of thyrotoxicosis fails. Plasmapheresis allows rapid removal of iodine and excess thyroid hormones from circulation. Plasmapheresis might play a role before total thyroidectomy in patients with severe AIT who are refractory to intensive pharmacological therapy and, perhaps, in patients who need continued AMIO treatment [62, 63] . In our opinion, haemodynamically non-stable patients have poor prognosis associated with plasmapheresis, especially when heart failure deteriorates, associated with long exposure to excess thyroid hormone and other AMIO adverse events (mainly lung toxicity). In Krakow's Centre of Endocrinology one patient with severe AIT was submitted to plasmapheresis and died due to respiratory failure [64] .
Total thyroidectomy
Total thyroidectomy is not the first-line treatment for AIT, especially in patients with severe cardiac disorders. However, this approach may be necessary in patients who are resistant to other treatments [65] [66] [67] . Recent studies have shown that total thyroidectomy can be performed in AIT patients without serious complications [68] [69] [70] [71] . Pierret et al. [72] performed 11 thyroidectomies in patients with AIT: 9 patients had no morbidity after elective surgery, while 2 patients required emergency surgery for multiple organ failure and cardiac problems. Immediate post-operative complications occurred in both cases [72] . However, the decision is
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difficult, and mainly centres with experienced endocrinologists, cardiologists, and surgeons should qualify for this treatment. In our opinion, surgery should not be delayed if haemodynamic status deteriorates [72] . Total thyroidectomy by rapidly restoring euthyroidism may improve cardiac function and reduce the risk of mortality in AIT patients with severe left ventricular systolic dysfunction [73] . To obtain a better control of thyrotoxicosis before surgery, a short course of iopanoic acid (in association with ATDs) [58] or plasmapheresis before surgery can be used. To avoid serum T3 surge after iopanoic acid withdrawal one should continue iopanoic acid for 7-10 days after surgery, particularly in patients with very high serum thyroid hormone concentrations before surgery. Appropriate preparation of AIT patient candidates to thyroidectomy is mandatory, using b-blockers and glucocorticoids [65] . In our opinion, surgery is safer than plasmapheresis and more effective. Surgery may be necessary even in the early stages of the disease, particularly during thyroid storm when immediate control of thyrotoxicosis is necessary and could be life saving. It is very important to make decision about operation in the proper time to keep the patient safe. In the Endocrinology Department in Krakow successful total thyroidectomy was performed in some cases of life-threatening AIT that were unresponsive to pharmacological treatment. Preoperative treatment with MMI IV, perchlorate, IV glucocorticoids, and b-blockers was performed. [64] . Surgery should be also performed as a definitive form of therapy in patients with suspicion of thyroid malignancy, large goitres, or compression of the trachea. A skilled surgeon and thorough preoperative anaesthesiological assessment are warranted.
RAI therapy
RAI therapy is usually not feasible in AIT patients because of low RAIU [2, 74] . An open study suggested, however, that RAI may have some value also in these cases, especially in patients with a predominately type 1 AIT [75] . Moreover, a recent report of four patients with type 2 AIT showed that, despite low RAIU values (< 4%), treatment with high doses (29-80 mCi) of RAI could restore euthyroidism or induce hypothyroidism [76] . In the Department of Endocrinology in Poznan RAI therapy was given in AIT patients with low RAIU, and none of their patients required a second RAI therapy [75] . Thyroid RAIU values might be increased by the administration of recombinant human TSH in type 1 AIT [77] . This approach may be risky, because recombinant human TSH administration in these patients may be followed by a sustained increase in serum thyroid hormone concentrations [78] .
Thyroid arterial embolisation in patients with AIT Thyroid arterial embolisation might represent a possible alternative in particular cases, but evidence on its effectiveness and safety in AIT patients is limited [79] .
Controversies associated with AIT
Should AMIO be continued or withdrawn in AIT?
The decision of whether AMIO therapy can be discontinued requires a strict interaction between cardiologists and endocrinologists. It is often not possible, from the cardiological point of view, to withdraw this drug. Because AMIO (and/or iodine) is the cause of thyroid damage and related thyrotoxicosis in type 2 AIT, its withdrawal should ideally be beneficial. On the other hand, due to the long half-life of the drug [80] , AMIO discontinuation might prove useless, at least in the short run. A few small studies suggested that continuing AMIO therapy does not reduce the cure rate of AIT patients receiving ATDs, glucocorticoids, or a combination of the two treatments [59, 80, 81] . Likewise, one study showed that continuation of AMIO treatment does not significantly affect the first normalisation of serum thyroid hormone levels in type 2 AIT patients treated with glucocorticoids [82] . However, the final cure time was significantly longer, and the final cure rate was lower in patients taking AMIO, although not reaching a statistical significance, probably due to the small sample size [82] . The observation that AMIO-taking patients achieved euthyroidism later than patients discontinuing AMIO argues against the idea that continuing AMIO therapy is devoid of any effect on the therapeutic outcome. This concept is reinforced by the observation that the recurrence rate of thyrotoxicosis was significantly more frequent in AIT patients continuing AMIO [82] . Furthermore, most patients taking AMIO had more frequently severe cardiac diseases than those discontinuing AMIO. In conclusion, AMIO continuation in type 2 AIT patients is associated with a longer cure time and delayed restoration of euthyroidism [82] . If cardiac conditions are stable and euthyroidism is expected to be restored in a short time (likely < 40 days), AMIO can be safely discontinued and eventually reinstituted after euthyroidism restoration; if cardiac conditions are unstable and require AMIO continuation, the drug should not necessarily be withdrawn. In the latter situation, a balance between longer exposure of the heart to thyroid hormone excess and a prompt control of thyrotoxicosis with total thyroidectomy should be considered [65, 69, 83] . The problem is more complex with type 1 and mixed/indefinite AIT cases. There are no controlled and prospective clinical studies on this issue, but the effects of iodine overload
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may last for several months after AMIO discontinuation [2] . In conclusion, endocrinologists often favour AMIO withdrawal, especially in type 1 AIT, if this is not risky for the patient from the cardiological standpoint.
The need to restart AMIO after a previous episode of AIT Evidence is scarce as to thyroid outcome after reinstitution of AMIO therapy following a previous episode of AIT. Data from the literature suggest that type 2 AIT may progress towards hypothyroidism, either spontaneously or after re-exposure to iodine load [84, 85] . Spontaneous progression towards hypothyroidism is in the long term much more frequent after type 2 AIT than after subacute thyroiditis [86] . This may not occur in type 1 AIT, because in this case the thyroid gland is intrinsically abnormal. Accordingly, while a periodical follow-up strategy is suggested in patients with type 2 AIT, prophylactic thyroid ablation (RAI or thyroidectomy) is frequently advised for type 1 AIT. If after restarting AMIO therapy hypothyroidism develops, AMIO should be continued and hypothyroidism should be treated with L-T4.
New drugs: alternative to AMIO?
Although several drugs that structurally resemble AMIO were tested, only dronedarone was registered for treating heart arrhythmias. Dronedarone (marketed as Multaq) is a non-iodinated benzofuran derivative of AMIO. Hence, dronedarone is less lipophilic than AMIO, with a much shorter half-life (24 hours) than AMIO [87] . Dronedarone does not appear to cause any of the thyroid, lung, and neurological adverse effects reported with AMIO. Dronedarone has been the subject of seven randomised controlled phase II/III clinical trials assessing its clinical efficacy in over 7000 patients [87, 88] . It has proven to be superior to placebo in terms of rate control among patients with AF (atrial fibrillation) and in the prevention of AF recurrence following cardioversion. However, the only head-to-head comparison with AMIO of 504 patients demonstrated the superiority of AMIO over dronedarone in preventing AF recurrence [89] . Nevertheless, the FDA approved dronedarone on 2 July 2009, as did the National Institute for Health and Clinical Excellence (NICE) in 2010 [90] . According to the guidelines of European Society of Cardiology from 2012, dronedarone should be avoided in patients with symptomatic heart failure and/or ejection fraction less than 35%, and also in patients with permanent atrial fibrillation. Other, non-registered medications similar to AMIO are Celivarone and Budiodarone. Information on thyroid effects of these drugs is lacking.
Amiodarone-induced hypothyroidism
AIH is relatively more frequent than AIT in iodine-replete areas [91] . In the SAFE-Trial subclinical hypothyroidism, defined as a TSH of 4.5-10 mU/L with normal thyroid hormone levels [28] was detected in 25.8% of patients taking amiodarone, while overt hypothyroidism (TSH > 10 mU/L) occurred in 5% [28] . Apparently there is no clear association between the daily or cumulative doses of AMIO and the occurrence of AIH [92] , although some studies suggested that the incidence of AIH decreases to 5-10% after long-term treatment (≥ 1 year) with AMIO [91, 92] . This reduction in prevalence may result from adaptation of the thyroid autoregulatory mecha nisms to iodine excess. Chronic autoimmune thyroiditis is the main risk factor for the development and persistence of AIH, and is the likely explanation for the preponderance of AIH in female gender (female-to-male ratio: 1.5:1) [92] . AMIO may accelerate the natural course of chronic autoimmune thyroiditis via iodine-(or amiodarone-) induced thyroid cell damage [43] . The risk of develop ing AIH is 14-fold higher when a combination of pre-existing thyroid-directed autoantibodies and female gender is present than in men without thyroid autoimmunity [26, 92] . Other patients at risk are those who fail to escape from the Wolff-Chaikoff effect and develop permanent hypothyroidism [93] . AIH may, however, spontaneously remit, especially in the absence of underlying thyroid autoimmune disease [94] . According to clinical investigations, the predictors for AMIO-associated hypothyroidism were: baseline serum TSH levels > 1.4 mU/L, left ventricular function < 45%, and diabetes mellitus [95, 96] . It should be kept in mind that AMIO treatment per se, in the absence of hypothyroidism, is associated with increased TSH levels and lower fT3 levels, bradycardia, and also increased total and LDL cholesterol levels.
Clinical features
Symptoms of AIH are identical to those of AMIO-unrelated primary hypothyroidism, and include dry skin, fatigue, mental sluggishness, weakness, constipation, menorrhagia, and cold intolerance. AIH may worsen ventricular irritability, for example torsades de pointes, if hypothyroidism is sustained or severe. Less commonly, AIH has been associated with acute renal failure, which is reversible after treatment with L-thyroxin and discontinuation of AMIO [27] . Hypothyroidism may develop as soon as 2 weeks or as late as 39 months after institution of AMIO treatment [97] .
Diagnosis
Diagnosis of hypothyroidism is usually straightforward and is confirmed by the finding of a persistently high
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serum TSH concentration (> 10 mU/L) in combination with a low-normal (subclinical type) or overtly low fT4 [44, 92] . Low serum total T3 or fT3 concentrations are a less reliable indicator of hypothyroidism as they may occur in euthyroid patients during AMIO treatment [26] . Sometimes diagnosis can be troublesome because high serum TSH and low fT4 and especially low fT3 might reflect non-thyroidal illness in patients with severe cardiac or other non-thyroidal disorders [44] .
Management
AMIO should be continued at the discretion of the cardiologist, keeping in mind that spontaneous remission of hypothyroidism may occur. Withdrawal of AMIO therapy is far less important in AIH than in AIT. If AMIO treatment is discontinued, the decision to initiate L-thyroxin replacement can be delayed [2] ; if thyroid hormone treatment has been started, the dose of L-thyroxin should be adjusted according to maintain serum TSH levels within the normal range [98, 99] . Many patients without pre-existing thyroid disease become euthyroid within 2-4 months after quitting AMIO treatment. Because of AMIO effects on thyroid hormone metabolism, higher doses of T4 may be required [100, 101] . Particular caution is warranted to avoid overtreatment, in view of the frequent severe underlying cardiac problems. Treatment with L-thyroxin has no effect on the antiarrhythmic properties of AMIO [102] . The decision concerning treating subclinical hypothyroidism has to be made individually for each patient.
Amiodarone and pregnancy
AMIO has been assigned to pregnancy category D by the FDA. There are no data from controlled human pregnancy studies. AMIO should be given during pregnancy only when there are no alternatives and when the benefits outweigh the risks. AMIO and its metabolites cross the placenta; therefore, in severe cases of heart arrhythmias in the foetus, AMIO may be given. The average umbilical cord to maternal plasma drug concentration ratio ranges from 0.1 to 0.6. While there are numerous reports describing the safety of AMIO during pregnancy, some reports of congenital goitre, hypothyroidism and hyperthyroidism, foetal bradycardia, and growth and psychomotor retardation have also been reported [103] [104] [105] . It is recommended that neonates whose mothers were treated with AMIO should have complete thyroid function tests performed; in addition, foetal echocardiography should be considered in all pregnancies exposed to AMIO in the embryonic period. In a review of 64 pregnancies in which AMIO was given to the mother, 11 cases of hypothyroidism were reported, and only 2 newborns had transient hypothyroxinaemia [105] . Neurodevelopment assessment of the hypothyroid infants showed mild abnormalities, most often reminiscent of Non-verbal Learning Disability Syndrome; however, these features were also reported in some AMIO-exposed euthyroid infants, suggesting that there might be a direct neurotoxic effect of AMIO during foetal life [106] . It seems prudent to advise that foetal/neonatal hypothyroidism be treated, as soon as the diagnosis is made, even in utero, to avoid neurodevelopment abnormalities, although the latter may occur independently of hypothyroidism. Twelve cases with gestational exposure to AMIO were identified in Canada: of six newborns with first-trimester exposure, one had congenital nystagmus with synchronous head titubation, there was one case of transient neonatal hypothyroidism (9%), and one of transient neonatal hyperthyroidism (9%): a fourth child, exposed to AMIO from the 20 th week of gestation, had developmental delay, hypotonia, hypertelorism, and micrognathia [107] . AMIO is excreted into human milk, so breast-feeding should not be initiated or should not be continued if the mother is treated with AMIO.
Conclusions
AMIO remains a very effective and broadly used anti -
arrhythmic drug, with high efficacy and safety in patients with heart failure and decreased ejection fraction.
Recently developed drugs, similar to AMIO, might
be associated with less frequent abnormalities of thyroid function, but also with lower cardiac effectiveness than AMIO. 3. The potential occurrence of thyroid abnormalities/ dysfunctions during AMIO administration should not represent a contraindication to its use, if required by cardiac conditions. 4. A common-sense approach to thyroid status assessment before starting AMIO (if treatment is not emergent) and subsequent periodical monitoring of thyroid function allows identification of patients at increased risk of thyroid dysfunction, and facilitate its early detection and treatment. 5. The following tests should be performed before initiating AMIO therapy: serum TSH and fT4, TPOAb, and thyroid US. If possible, patients with decreased serum TSH concentration should undergo further evaluation before AMIO treatment: fT3, TRAb, and thyroid scintigraphy. TSH should be monitored at least every 6 months during AMIO therapy and 6-12 months after discontinuing therapy. 6. AIT remains a diagnostic and therapeutic challenge for the physician. Identification of different subtypes may be difficult and is often imprecise. The difficulty in the initial assessment may hamper a correct therapeutic approach.
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7. First-line treatment of AIT is generally medical. When a clear-cut diagnosis of type 1 AIT is made, thioamides are the first-line treatment; if type 2 AIT is diagnosed, glucocorticoids are the treatment of choice. In mixed/indefinite forms, combination therapy should be initiated. However, if rapid restoration of euthyroidism is necessary and the general conditions of the patient might further deteriorate due to uncontrolled thyrotoxicosis, total thyroidectomy is a valid therapeutic option. 8. The decision of whether to continue or withdraw AMIO in AIT remains complex. Due consideration must be given to the benefit of AMIO in lifethreatening arrhythmias and the harmful prolonged exposure to thyroid hormone excess. 9. Diagnosis of hypothyroidism is usually straightforward, but biochemical changes related to non-thyroidal illness (low T3 syndrome) and not reflecting hypothyroidism should be taken into account. Occurrence of AIH does not require AMIO withdrawal.
Polish version
Wstęp
Amiodaron (AMIO) jest jednym z najpowszechniej stosowanych leków antyarytmicznych [1] . Amiodaron należy do III klasy leków antyarytmicznych, po raz pierwszy opisany około 40 lat temu jako lek rozszerzający naczynia wieńcowe [1] . Jego właściwości antyarytmiczne zostały poznane w 1968 roku, zaś Amerykańska Agencja Żywności i Leków (FDA, Food and Drug Administration) zatwierdziła lek do stosowania w nawracających, zagrażających życiu komorowych zaburzeniach rytmu serca w 1985 roku [2, 3] . Aktualnie AMIO jest stosowany w wielu arytmiach, zarówno komorowych, jak i nadkomorowych, mimo że zalecenia FDA nie zmieniły się od 1985 roku.
Wpływ AMIO na funkcję tarczycy i metabolizm hormonów tarczycowych
Nadmiar jodu
Amiodaron jest pochodną benzofuranu, zawiera około 37% jodu, zaś strukturalnie wykazuje duże podobień-stwo do hormonów tarczycowych [4, 5] . Pacjent, który otrzymuje dziennie standardową dawkę leku (200 mg) dostaje 75 mg jodu organicznego na dobę, co znacznie przewyższa zalecaną dobową podaż jodu (150-200 ug). Metabolizm leku powoduje, że każdego dnia uwalnia się około 6 mg wolnego jodu [6, 7] . Nie jest jasne, czy AMIO samodzielnie, czy poprzez główny metabolit desethylamiodaron (DEA) wpływa na zmianę funkcji tarczycy. Desethylamiodaron powstaje w wyniku metabolizmu AMIO poprzez cytochrom P4503A (CYP3A), obydwie cząsteczki wykazują długi okres półtrwania, pomiędzy 40-58 dni i 36-61 dni, odpowiednio [8] [9] [10] . Lek kumuluje się w wielu tkankach i narządach organizmu, takich jak: tkanka tłuszczowa, wątroba, płuca, rzadziej w nerkach, sercu, mięśniach szkieletowych, tarczycy i mózgu [11] . Zdrowa tarczyca odpowiada na nadmiar jodu zahamowaniem syntezy hormonów tarczycowych (efekt Wolff-Chaikoff). Następnie w prawidłowej tarczycy występuje efekt ucieczki od efektu Wolffa-Chaikoffa (escape phenomena).
Zahamowanie konwersji T4 do T3
Powszechnie wiadomo, że przynajmniej częściowo efekt AMIO na tarczycę wynika z działania odpowiednich dejodynaz [12 ,13] . Amiodaron hamuje dejodynację tyroksyny (T4) poprzez hamowanie aktywności 5-dejodynazy (D1 i D2). Prowadzi to do zmniejszenia powstawania trójjodotyroniny (T3) z T4, zmniejszenia usuwania odwrotnej T3 (rT3), a w konsekwencji kumulację rT3 [14] .
Podobieństwo do T3
Budowa chemiczna AMIO i DEA jest podobna do struktury T3 i niektóre efekty leku mogą być wynikiem zahamowania transportu hormonów tarczycowych przez błonę komórkową [15] i/lub bezpośredniego łączenia się z receptorem dla hormonów tarczycowych [16, 17] , prawdopodobnie również z zależnej od receptora tarczycowego (TR) transkrypcji genów [18] . Dodatkowo, DEA jest niekompetycyjnym inhibitorem wiązania receptora (TR) b z hormonem tarczycowym (T3) [19] . Opisane powyżej zjawiska są przyczyną występowania efektów podobnych do niedoczynności tarczycy u pacjentów leczonych AMIO i pozostających w eutyreozie, włączając w to przejściowy wzrost TSH w surowicy [20] . Leczenie AMIO zmniejsza ekspresję genów wrażliwych na hormony tarczycowe, powodując down-regulation genów mięśnia serca, takich jak SERCA2A (sarco/endoplasmic reticulum calcium ATPase-2), gen łańcucha ciężkiego miozyny (aMHC) oraz zwiększa aktywność bMHC. Wszystkie te zjawiska są obserwowane w niedoczynności tarczycy [21, 22] . Dodatkowo zmniejszenie aktywności wątrobowego receptora dla LDL prowadzi do zwiększenia stężenia cholesterolu w surowicy krwi [23] .
Destrukcja tyreocytów
Amiodaron i DEA mają również bezpośredni toksyczny efekt na komórki tarczycowe, chociaż nadmiar jodu per se może być także odpowiedzialny za cytotoksyczność [24] .
Zmiany stężeń hormonów tarczycowych podczas leczenia AMIO
Tyreotropina jest pierwszym hormonem, którego wartość zmienia się, jego wartości wzrastają w ciągu 48 godzin i osiągają średnio 2,7-krotnie wyższą wartość od normalnej około 10 dnia leczenia [25] . Od początku terapii pojawia się efekt Wolffa-Chaikoffa, co powoduje obniżenie stężenia T4 i T3, jednak później (ok. 2 tygodnie) zaczyna pojawiać się efekt ucieczki. Wtedy pojawia się wczesny wzrost stężenia T4, rT3 i wolnej frakcji T4, który osiąga szczyt po 10 tygodniu leczenia [11] . Przeciwnie, w tym samym czasie wartości T3 obniżają się. W ciągu 3 miesięcy leczenia ustala się stałe stężęnie w surowicy krwi dla całkowitej i wolnej frakcji T4 oraz rT3, pozostają one w górnym przedziale normy lub nieznacznie podwyższone. Wartości T3 mają tendencję do utrzymywania się w dolnych granicach normy po 3 miesiącach leczenia, zaś TSH w górnym przedziale normy. Podczas długotrwałej terapii AMIO może pojawić się obniżenie wartości TSH [2] (tab. I).
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Działania niepożądane długotrwałej terapii AMIO
Długotrwałe stosowanie AMIO może wiązać się z wieloma działaniami niepożądanymi (tab. II) [26] . Większość pacjentów pozostaje w eutyreozie podczas leczenia AMIO, u około 15-20% rozwijają się zaburzenia funkcji tarczycy, które mogą przebiegać od postaci bezobjawowych do pełnoobjawowej choroby, zarówno niedoczynności indukowanej AMIO (AIH, amiodarone--induced hypothyroidism), jak i nadczynności tarczycy (AIT, amiodarone-induced thyrotoxicosis) [27] . Zaburzenia funkcji tarczycy mogą pojawić się w dowolnym momencie podczas leczenia [28] . Kontrola parametrów tarczycowych jest konieczna przed włączeniem leczenia, okresowo podczas leczenia oraz do 6-12 miesięcy po zakończonym leczeniu. Należy również pamiętać o pozatarczycowych działaniach ubocznych AMIO (tab. II), ponieważ w szczególności powikłania płucne i wątrobowe mogą pogarszać przebieg AIT [29] .
Kontrola homonalna podczas leczenia AMIO
Podstawowe badania powinny obejmować: -TSH i fT4 (i fT3, jeżeli konieczne) -przeciwciała przeciwtarczycowe anty-TPO i anty-TG -USG tarczycy (US). Chociaż większość towarzystw endokrynologicznych nie zaleca rutynowego wykonywania badania USG, badanie to jest pomocne w krajach z dużą częstością występowania wola guzowatego, może również sugerować lub potwierdzić obecność autoimmunizacyjnej choroby tarczycy. Pacjenci z obniżonym/zahamowanym TSH powinni mieć wykonane dodatkowe badania diagnostyczneprzeciwciała przeciw receptorowi dla TSH (TRAb) oraz scyntygrafię tarczycy [30] . U pacjentów z subkliniczną nadczynnością tarczycy spowodowaną obecnością toksycznego wola guzowatego lub chorobą Gravesa i Basedowa należy rozważyć ablację tarczycy (radiojod lub usunięcie tarczycy), przed rozpoczęciem leczenia AMIO, jeśli jest to możliwe. Podczas leczenia AMIO należy kontrolować funkcję tarczycy przynajmniej co 6 miesięcy. Zaleca się kontrolę funkcji tarczycy przed leczeniem AMIO oraz 1 miesiąc i 3 miesiące po włą-czeniu leczenia, następnie w trakcie trwania terapii AMIO w odstępach co 3-6 miesięcy. Nie jest zalecana kontrola przeciwciał przeciwtarczycowych w trakcie leczenia AMIO, ponieważ terapia AMIO nie wiąże się z pojawieniem się autoimmunizacyjnej choroby tarczycy.
Nadczynność tarczycy indukowana AMIO
Nadczynność tarczycy indukowana AMIO występuje 3-krotnie częściej u mężczyzn niż u kobiet [31] . NadTabela I. Zmiany stężeń hormonów tarczycowych u pacjentów w eutyreozie podczas terapii AMIO Układ sercowo-naczyniowy < 10% Bradykardia (5%), wydłużenie QT, bloki serca, rzadko (< 1%) torsades de pointes
Układ oddechowy 1-17% Lipoidowe zapalenie płuc (zwykle bezobjawowe), efekt toksyczny pod postacią pneumonitis (0,1-1,6%) (przewlekły kaszel, trudności z oddychaniem i nacieki śródmiąższowe w RTG), bardzo rzadko zespół niewydolności oddechowej dorosłych (ARDS) Skóra ≤ 75% Wrażliwość na słońce (25-75%), ciemnoszara pigmantacja (< 10%), łysienie (< 10%) Wątroba ≤ 30% Nieprawidłowości w testach wątrobowych (< 30%), zapalenie wątroby, marskość (< 3%)
Układ nerwowy 3-35% Drżenie, problemy z pamięcią, poznawcze. Czuciowo-ruchowa polineuropatia (≤ 1%) zlokalizowana głównie dystalnie, zapalenie i neuropatia nerwu wzrokowego (≤ 1%) Oczy ≤ 100% Oczy (≤ 100%), mikrodepozyty rogówki (100%) -odwracalne po zakończeniu leczenia. Zapalenie i neuropatia nerwu wzrokowego
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czynność tarczycy indukowana AMIO zwykle wystę-puje po kilku miesiącach leczenia AMIO, ale może też wystąpić w ciągu kilku początkowych tygodni leczenia [32] . Początek AIT zależy od typu AIT, krótszy jest w przypadku typu 1 niż w typie 2 (patrz poniżej) [33] . Objętość tarczycy również wpływa na czas wystąpie-nia AIT [33] . Z powodu długiego okresu półtrwania AMIO, AIT może również pojawić się kilka miesięcy po zakończeniu leczenia [34] . Wyróżniamy dwa główne typy AIT. Typ 1 AIT występuje u pacjentów z wcześ-niejszą patologią tarczycy, taką jak wole guzowate czy utajona choroba Gravesa-Basedowa. U tych chorych nagłe obładowanie jodem spowodowane stosowaniem AMIO, może wyzwolić zwiększoną syntezę hormonów w gruczole tarczowym i wywołać jawną nadczynność tarczycy (efekt Jod-Basedow) [26] . Typ 2 AIT pojawia się u pacjentów z prawidłową lub nieznacznie powiększoną tarczycą i wynika bezpośrednio z toksycznego działania AMIO (lub jodu), wywołując zapalenie tarczycy z rozpadem [24] . Badanie histopatologiczne tkanki tarczycowej może potwierdzić obecność procesu zapalnego, nacieki histiocytów oraz włóknienie [35] . Zdarza się, że różnicowanie obu typów AIT jest trudne. W niektórych przypadkach oba typy AIT oraz patomechanizmy odpowiedzialne za wystą-pienie choroby mogą współistnieć u jednego chorego, taki typ nazywamy mieszanym lub niezdefiniowanym (tab. III).
W ciągu ostatnich 20 lat trend dotyczący występo--wania typów AIT zmienił się. Aktualnie typ 2 występuje częściej, jest to około 90% wszystkich przypadków AIT.
Nie do końca znane są przyczyny tego stanu, należy wziąć pod uwagę fakt, że pacjenci kwalifikowani do leczenia AMIO są dokładnie badani w kierunku występowania chorób tarczycy w porównaniu z tym co było w przeszłości [35] .
Kliniczne objawy AIT
Większość objawów AIT jest podobna do tych wystę-pujących w nadczynności tarczycy o innej etiologii i obejmują spadek masy ciała, nietolerancję ciepła, męczliwość, osłabienie siły mięśniowej, biegunki, skąpe miesiączkowanie, nerwowość i kołatanie serca. Dodatkowo u chorych z AIT mogą występować następujące objawy: -AIT często występuje u osób starszych, u osób tych może występować apatia, spadek apetytu czy depresja [36] . U chorych powyżej 60. roku życia ponad 50% może mieć typowe objawy nadczynności tarczycy, przy czym dominuje spadek masy ciała; -nawrót lub zaostrzenie choroby serca lub arytmii podczas leczenia AMIO u chorych, u których wcześniej choroba serca była dobrze kontrolowana może być pierwszym objawem AIT [37, 38] ; -wielu chorych z migotaniem przedsionków jest leczonych lekami przeciwkrzepliwymi, aby zmniejszyć ryzyko zakrzepowo-zatorowe. Warfaryna hamuje syntezę czynników krzepnięcia zależnych od witaminy K (II, VII, IX i X). W nadczynności tarczycy farmakokinetyka warfaryny nie zmienia się, jednak zwiększa się degradacja czynników krzepnięcia zależnych od witaminy K, co nasila efekty 
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działania warfaryny. Uważa się, że niewyjaśniona zwiększona wrażliwość na warfarynę oraz konieczność zmniejszenia jej dawki pozwala podejrzewać nadczynność tarczycy [39, 40] . Amiodaron może wpływać na metabolizm warfaryny per se, niezależnie od nadczynności tarczycy; obecność zaburzeń genetycznych wpływających na metabolizm warfaryny (CYP2C9*3/*3, VKORC1*3/*3) może dodatkowo zwiększać ryzyko przedawkowania leku [41] . Leczenie warfaryną u chorych z AIT powinno być wprowadzane powoli, zaczynając od małych dawek leku; -niezależnie od stężenia hormonów tarczycowych, przebieg AIT może być skąpoobjawowy, szczególnie na początku choroby. Skąpoobjawowy przebieg choroby może być przyczyną pomyłek diagnostycznych. Przebieg taki może wynikać z fizjologicznego działania AMIO, takiego jak: antagonistyczny efekt na receptory b-adrenergiczne, hamowanie dejodynacji T4 do T3, blokada wiązania hormonów tarczycowych do receptora T3 w sercu. -z drugiej strony, AIT może charakteryzować się bardzo ciężkim przebiegiem, szczególnie u osób młodych, u których kliniczna manifestacja jest identyczna jak w przypadku spontanicznej nadczynności tarczycy [25, 31, 42] .
Różnicowanie nadczynności tarczycy indukowanej amiodaronem
Większość ośrodków wyróżnia dwa główne typy AIT, ponieważ ich leczenie i przebieg znacząco się różnią [42] . Niektóre ośrodki zalecają leczenie wszystkich chorych z AIT w ten sam sposób, zaczynając od metimazolu (MMI) i steroidów; takie postępowanie wymaga sprawdzenia w różnych populacjach (np. odnośnie spożycia jodu). Zahamowane TSH i podwyższone fT4 oraz fT3 występują w obu typach AIT i nie różnicują typu choroby. Zwiększony (> 4) stosunek T4/T3 jest bardziej charakterystyczny dla zapalenia tarczycy z rozpadem [43] , ale nie jest istotnie pomocne w indywidualnych przypadkach chorych z AIT, ponieważ w chorobie tej fT4 jest zwykle wyższe od fT3 i wynika to z hamowania dejodynazy D1 [35] . Poszukiwanie typowych przeciwciał (szczególnie przeciwko receptorowi dla TSH) jest wskazane u pacjentów, u których podłoża choroby leży najpewniej choroba Gravesa-Basedowa [2] . Tylko 8% pacjentów z typem 2 AIT ma obecne przeciwciała przeciwtarczycowe w badaniach laboratoryjnych. U pacjentów w eutyreozie, z utajonym autoimmunizacyjnym zapaleniem tarczycy, AMIO może wywołać proces rozpadu tarczycy, prowadząc do rozwoju typu 2 AIT [35, 44] . Oznaczanie innych wskaźników, takich jak interleukina-6, białko C-reaktywne, tyreoglobulina nie jest użyteczne w praktyce klinicznej [45] . Wychwyt jodu (RAIU) zwykle jest niski w typie 1 AIT, ale może być prawidłowy lub podwyższony z powodu obecności autonomicznej tkanki tarczycowej. Przeciwnie, w typie 2 wychwyt jest bardzo niski lub całkowicie zahamowany z powodu rozpadu i zniszczenia tkanki tarczycowej [26] . Wyniki dotyczące RAIU różnią się zależnie od publikacji, prawdopodobnie z powodu różnic w kwalifikacji chorych do badań oraz obecności czynników wpływających na wychwyt jodu (np. spożycie jodu), co ostatecznie mogło wpłynąć na wyniki [44] . Ostatnio, scyntygrafia tarczycy z użyciem [99mTc]2--methoxy-isobutyl-isonitrile (MIBI) była proponowana jako badanie potencjalnie pomocne w różnicowaniu typów AIT [46] . W jednym badaniu stwierdzono obecność wychwytu znacznika w typie 1 AIT, co sugeruje nadczynność tkanki tarczycowej, podczas gdy w typie 2 nie stwierdzono obecności wychwytu MIBI; 4 pacjentów z nieokreślonym typem AIT miało również nieznaczny, przetrwały wychwyt MIBI oraz szybkie wypłukiwanie znacznika [46] . Mimo obiecujących wyników, badanie wymaga oceny większej grupy chorych i nie jest jeszcze stosowane w praktyce klinicznej.
Badanie USG tarczycy często wykazuje obecność wola, obniżoną echogeniczność i/lub zmiany ogniskowe w typie 1 AIT, zaś w typie 2 AIT obraz tarczycy w badaniu USG jest zwykle prawidłowy lub może występować niewielkie wole. Jednak tradycyjna sonografia nie daje informacji dotyczących czynności gruczołu, zaś obecność wola/guzków nie zawsze przesądza o mechanizmie AIT. Ultrasonografia z użyciem Dopplera może ujawnić prawidłowy/zwiększony przepływ (w gruczole nadczynnym) w większości przypadków AIT typu 1 lub zmniejszony/brak przepływu (rozpad gruczołu) w 2 typie AIT [47, 48] . Ocena tarczycy w badaniu USG jest niezbędna dla prawidłowego rozpoznania.
Różnicowanie między oboma typami AIT jest waż-ne, ponieważ ma bezpośredni wpływ na postępowanie z chorym. Zastosowanie kilku narzędzi diagnostycznych poprawia różnicowanie AIT, ale niekiedy może być zawodne.
Postępowanie w nadczynności tarczycy indukowanej amiodaronem
Nadczynność tarczycy indukowana amiodaronem niesie za sobą 3-krotnie większe ryzyko ciężkich powikłań sercowo-naczyniowych niż u osób w eutyreozie, z tego powodu najważniejsze jest szybkie włączenie odpowiedniego leczenia [38, 49, 50] . Decyzja dotycząca kontynuowania lub zaprzestania stosowania AMIO jest trudna i nie ma w tym względzie jednoznacznego konsensusu. Przy podejmowaniu decyzji z jednej strony należy brać pod uwagę pozytywny efekt AMIO na zagrażające życiu zaburzenia rytmu serca,
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z drugiej strony należy również pamiętać, że AMIO ma długi okres półtrwania (dlatego brak jest natychmiastowej poprawy w zakresie czynności tarczycy po jego odstawieniu), oraz dodatkowo zmniejsza on konwersję T4 do T3. Z tego powodu po odstawieniu AMIO może się pojawić zaostrzenie objawów sercowych oraz nasilenie objawów nadczynności tarczycy [38, 51] . Istotne jest również, że DEA wiąże się z wewnątrz--komórkowym receptorem dla T3 i działa jako antagonista T3, stąd kontynuowanie stosowania AMIO i leczenie lekami przeciwtarczycowymi (ATDs) może być jedyną opcją u niektórych chorych [19] .
może przywrócić eutyreozę lub wywoływać niedoczynność tarczycy [76] . W Klinice Endokrynologii w Poznaniu leczono RAI chorych z AIT z niskim RAIU i żaden z leczonych pacjentów nie wymagał terapii RAI po raz drugi [75] . Wartości RAIU może zostać zwiększo-na poprzez podawanie rekombinowanego ludzkiego TSH u chorych z AIT typu 1 [77] . Podejście to może być ryzykowne, ponieważ rekombinowany ludzki TSH u tych chorych może spowodować wystąpienie trwałego wzrostu stężenia hormonów tarczycy w surowicy [78] .
Embolizacja tętnicy tarczowej u chorych z AIT Embolizacja tętnicy tarczowej może stanowić potencjalną alternatywę w niektórych przypadkach, ale brak jest dowodów na efektywność i bezpieczeństwo takiego leczenia u chorych z AIT [79] .
